UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):
November 7, 2006
GENZYME CORPORATION
(Exact name of registrant as specified in its charter)
Massachusetts |
| 0-14680 |
| 06-1047163 |
(State or other jurisdiction of incorporation or organization) |
| (Commission file number) |
| (IRS employer identification number) |
500 Kendall Street, Cambridge, Massachusetts 02142
(Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code:
(617) 252-7500
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
On November 7, 2006, Genzyme Corporation announced it had completed its all cash tender offer to acquire AnorMED Inc. and subsequently completed a compulsory acquisition of any AnorMED common shares that were not tendered in the tender offer. A copy of the press release is included as Exhibit 99.1 hereto.
1
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| GENZYME CORPORATION | |||
|
|
|
|
|
Dated: November 9, 2006 |
| By: |
| /s/ Peter Wirth |
|
|
|
| Peter Wirth |
|
|
|
| Executive Vice President and |
|
|
|
| Chief Legal Officer |
2
Item 9.01 Financial Statements and Exhibits.
(c) Exhibits
99.1 Press Release of Genzyme Corporation dated November 7, 2006.*
* Previously filed as Exhibit (a)(16) to Genzyme Corporation’s Amendment No. 5 to its Tender Offer Statement on Schedule TO-T/A (File No. 005-81132) and incorporated herein by reference thereto.
3